Abstracts tagged "Cutaneous"

Abstract Number: 1577 • ACR Convergence 2022
Impact of Cutaneous Vasculitis on Health-Related Quality-of-Life
Sarah Mann¹, Aamir Hussain², Anisha Dua³, Angelina Patrone⁴, Kalen Larson⁵, Peter Merkel⁶ and Robert Micheletti⁷, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology, Georgetown University, Washington, DC, ³Northwestern University, Chicago, IL, ⁴Patient Partner, Philadelphia, PA, ⁵Vasculitis Foundation, Kansas City, MO, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Departments of Dermatology and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cutaneous manifestations of vasculitis can cause pruritus, pain, and ulceration, and their psychosocial impacts may be significant. However, the quality-of-life (QoL) impact of skin…
Abstract Number: 1664 • ACR Convergence 2022
TRIM21 as a Regulator of UVB-Driven IFN Responses in Lupus
Richard Moore, Gantsetseg Tumurkhuu, Daniel Wallace and Caroline Jefferies, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Patients with systemic lupus erythematosus (SLE) experience photosensitivity where exposure to ultraviolet light B (UVB) drives lupus flares and systemic symptoms. Although the mechanisms…
Abstract Number: 1692 • ACR Convergence 2022
Interferon Alpha Promotes Ultraviolet Light-Mediated Keratinocyte Apoptosis in a Caspase-8 Dependent Manner via Upregulation of Interferon Regulatory Factor 1
Shannon Estadt, Mehrnaz Gharaee-Kermani, Bin Xu, Tyson Moore, Andrew Hannoudi and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by enhanced sensitivity to ultraviolet radiation (UVR). UVR can trigger cutaneous and systemic disease…
Abstract Number: 1696 • ACR Convergence 2022
Single Cell RNA-seq Identifies Major Shifts in Myeloid Cells in Dermatomyositis Skin and Peripheral Blood Compared to Systemic Lupus
Grace Hile, Feiyang Ma, Amanda Victory, Bin Xu, Mehrnaz Gharaee-Kermani, Elisabeth Pedersen, Rachael Wasikowski, Celine Berthier, Vladimir Ognenovski, Allison Billi, Johann Gudjonsson and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Skin disease in dermatomyositis (DM) is relapsing and often refractory to treatment, reflecting a lack of understanding of the mechanisms driving skin inflammation. DM…
Abstract Number: 1710 • ACR Convergence 2022
CCL2 Drives Interferon-enhanced Monocytosis in UV-mediated Skin Injury in Murine Lupus
Mitra Maz¹, Hong Shi², Sonya Wolf-Fortune³, Shannon Estadt³, Alayka Reddy³, Rachael Wasikowski³, Alex Tsoi³, Celine Berthier³ and J. Michelle Kahlenberg³, ¹University of Michigan Medical School, Ann Arbor, MI, ²Department of Internal Medicine/Division of Rheumatology, Vascular Biology Center, Augusta, GA, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by overproduction of type I interferons (IFNs) and sensitivity to ultraviolet (UV) light. Though…
Abstract Number: 0208 • ACR Convergence 2022
Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score (CDASI-A) and Associated Patient-Reported Outcomes and Biomarkers in a Phase 2 Clinical Trial in Dermatomyositis (DM)
Josh Dan¹, Jay Patel², Grant Sprow³, DeAnna Diaz⁴, Nilesh Kodali⁵, Rui Feng⁶, Barbara White⁷ and Victoria Werth⁸, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ²Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PN, ³Albert Einstein College of Medicine, Philadelphia, PA, ⁴Philadelphia College of Medicine, Philadelphia, PA, ⁵New Jersey Medical School, Coppell, TX, ⁶University of Pennsylvania, Philadelphia, ⁷SFJ Pharmaceuticals, Towson, MD, ⁸University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: Retrospective reviews of clinical databases from two sites have identified strong relationships between patient-reported outcomes and skin activity in DM, as measured by CDASI-A.…
Abstract Number: 1766 • ACR Convergence 2022
COVID-19 Cutaneous and Systemic Manifestations Among Race: A Systematic Review and Meta-Analysis
Angie El-Said¹, Areeb Ahmad², Massimo Valenti³, Neel K. Shah¹, Susana Soto¹ and Shazia Beg⁴, ¹University of Central Florida College of Medicine, Orlando, FL, ²University of Central Florida, Orlando, FL, ³Sapienza University of Rome, School of Medicine, Rome, Italy, ⁴UCF, Orlando, FL
Background/Purpose: Although various systemic and dermatologic manifestations associated with COVID-19 have been reported in the literature, investigations of how these manifestations vary by race remain…
Abstract Number: 0211 • ACR Convergence 2022
Determinants of COVID-19 Vaccine Hesitancy in a Predominantly Black Population with Cutaneous Lupus Erythematosus
Sophia Lutgen¹, S. Sam Lim², Laura D. Aspey², Gaobin Bao³, Charmayne Dunlop-Thomas², Jessica N. Williams² and Cristina Drenkard², ¹Mount Sinai Morningside-West, New York, NY, ²Emory University, Atlanta, GA, ³Emory University School of Medicine, Atlanta, GA
Background/Purpose: Due to demographic and disease-related factors, patients with lupus are deemed to be more vulnerable to COVID-19 infection than the general population, but they…
Abstract Number: 1848 • ACR Convergence 2022
Characterizing Nailfold Capillary Changes in Dermatomyositis with a Dermatoscope
Josh Dan¹, Grant Sprow², Josef Concha³, Nilesh Kodali⁴, DeAnna Diaz⁵, Felix Chin⁶, Thomas Vazquez⁷ and Victoria Werth³, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ²Albert Einstein College of Medicine, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴New Jersey Medical School, Coppell, TX, ⁵Philadelphia College of Medicine, Philadelphia, PA, ⁶University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁷FIU Wertheim College of Medicine, Virginia Beach, VA
Background/Purpose: Nailfold capillary (NC) abnormalities are increasingly utilized in the evaluation of rheumatic conditions. Their presence can distinguish primary Raynaud's phenomenon from secondary etiologies and…
Abstract Number: 0318 • ACR Convergence 2022
Development and Validation of Algorithms to Identify Cutaneous Lupus Patients Using Diagnostic Codes and Prescription Data
Lisa Guo¹, Jordan Said², Vinod Nambudiri³ and Joseph Merola³, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Harvard Medical School, Brigham and Women's Hospital, Boston, MA
Background/Purpose: There is a paucity of epidemiological studies of cutaneous lupus erythematosus (CLE), which may be due in part to the lack of well-validated methods…
Abstract Number: 1862 • ACR Convergence 2022
Lenabasum Reduces IFNγ and pIRF3 in Dermatomyositis Skin: Biomarker Results from a Double-Blind Phase 3 International Randomized Controlled Trial
Thomas Vazquez¹, Meena Sharma¹, Rui Feng², DeAnna Diaz³, Nilesh Kodali¹, Josh Dan³, Madison Grinnell³, Emily Keyes³, Grant Sprow³, Barbara White⁴ and Victoria Werth³, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁴Corbus Pharmaceuticals, Pleasanton, CA
Background/Purpose: Dermatomyositis (DM) is an autoimmune connective tissue disease that primarily affects the skin and lung; few effective treatment options are available. Lenabasum is a…
Abstract Number: 0335 • ACR Convergence 2022
Multiplexed Mass Cytometry of Cutaneous Lupus Erythematosus and Dermatomyositis Skin: An In-depth B Cell Directed Immunoprofile
Mariko Ogawa-Momohara¹, Thomas Vazquez², Meena Sharma², Josh Dan³, Grant Sprow³ and Victoria Werth³, ¹Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia
Background/Purpose: Cutaneous lupus erythematosus (CLE) and dermatomyositis (DM) are both characterized histologically by interface dermatitis with a perivascular and periadnexal lymphocytic infiltrate, requiring clinical correlation…
Abstract Number: 2267 • ACR Convergence 2022
Plasmacytoid Dendritic Cells Are Not Major Producers of Type 1 Interferons in Cutaneous Lupus
Thomas Vazquez¹, Nilesh Kodali¹, DeAnna Diaz², Jay Patel³, Emily Keyes², Grant Sprow², Meena Sharma¹, Mariko Ogawa-Momohara², Madison Grinnell², Josh Dan² and Victoria Werth², ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PN
Background/Purpose: Type 1 interferons (IFN-1) are major drivers of disease activity in systemic (SLE) and cutaneous lupus erythematosus (CLE). Plasmacytoid dendritic cells (pDCs) are the…
Abstract Number: 0348 • ACR Convergence 2022
Significant Improvement in Cutaneous Lupus Erythematosus with or Without Systemic Lupus Erythematosus with Belimumab Use – a Systematic Review and Meta-Analysis
Rachel Kneeland¹, Daniel Montes¹, Justin endo¹, Bridget Shields¹, Christie Bartels² and Shivani Garg³, ¹University of Wisconsin, School of Medicine and Public Health, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI, ³University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Cutaneous lupus erythematosus (CLE) with or without systemic lupus erythematosus (SLE), can be debilitating and cause significant scarring and psychological distress. Belimumab, a monoclonal…
Abstract Number: 0364 • ACR Convergence 2022
Efficacy of BIIB059 on Joint and Skin Manifestations in Participants with Systemic Lupus Erythematosus (SLE): Exploratory Analyses of the Phase 2, Randomized, Double-Blind, Placebo-Controlled LILAC Study (Part A)
Richard Furie¹, Ronald van Vollenhoven², Victoria Werth³, Kenneth Kalunian⁴, Sandra Navarra⁵, Juanita Romero-Diaz⁶, Ting Wang⁷, Cristina Musselli⁷, Catherine Barbey⁸ and Nathalie Franchimont⁷, ¹Northwell Health, Great Neck, NY, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁴University of California San Diego, La Jolla, CA, ⁵University of Santo Tomas, Manila, Philippines, ⁶Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, ⁷Biogen, Cambridge, MA, ⁸Biogen, Baar, Switzerland
Background/Purpose: SLE is a heterogeneous illness that often manifests with skin and/or joint diseases.1 BIIB059 is a humanized monoclonal antibody that binds to BDCA2, a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].